Jiangsu Cowin Biotech Co. Ltd. A (688426) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Jiangsu Cowin Biotech Co. Ltd. A stock ¥7.89, price ¥17.57, upside -55.1%, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.
How to read this chart
48‑month range ¥14.95 – ¥44.73 · fair‑value band ¥5.21 – ¥9.86 · the ¥17.57 price screens above the ¥7.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 30, 2026.
Follow Jiangsu Cowin Biotech Co. Ltd. A in your weekly email
Every Wednesday you see whether Jiangsu Cowin Biotech Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Jiangsu CoWin Biotech Co., Ltd. engages in the research and development, production, and sale of biological products in China.
Show moreShow less
The company provides molecular diagnostic raw material enzymes, nucleic acid collection and protection agents, nucleic acid extraction and purification kits, molecular diagnostic testing reagents, etc.
It also offers medical device products, nucleic acid collection and protection, PCR, RT-PCR, and qPCR products, molecular diagnosis, isothermal amplification, nucleic acid mass spectrometry, next generation sequencing, nucleic acid extraction and purification, marker clone transfection, antibody, protein detection products, and scientific research instruments.
The company was founded in 2010 and is headquartered in Taizhou, China.
Stock analysis
Jiangsu Cowin Biotech Co. Ltd. A (688426) currently trades at ¥17.57, while our model-based Fair Value estimate is ¥7.89, 55.1% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the data coverage at low.
Scenario range: ¥5.21 (bear) to ¥9.86 (bull), the price of ¥17.57 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Jiangsu Cowin Biotech Co. Ltd. A reported revenue of 194M CNY in FY2025 versus 338M CNY in FY2021, a compound −13.0%/yr. Reported net income was −107M CNY in FY2025.
Key figures
Market cap 2.0B CNY (≈ $297M) Micro · P/S ratio 9.35 · EPS (TTM) ¥−0.7600 · Dividend yield 0.0% · Net margin −39.5% · Return on equity −6.6% · Return on assets (EBIT) 1.7% · Operating margin −50.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −55%, 688426 screens richer than that median.
Fair Value models
Bear¥5.21Fair Value ¥7.89Bull¥9.86
Price ¥17.57 · Upside -55.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+53.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−28.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.7%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
53.6% (2020) → −62.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Jiangsu Cowin Biotech Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 588 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score46 · Above median
Fair Value upside−55.1% · Below median
Profitability
Return on assets−7.2% · Above median
Net margin (12 months)−39.5% · Bottom 25%
Operating margin (12 months)−50.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)22.5% · Above median
Dividend yield (12 months)0.0% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.46× · Cheaper than median
P/S (12 months)9.01× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jiangsu Cowin Biotech Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688426
Frequently asked questions
Is Jiangsu Cowin Biotech Co. Ltd. A (688426) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of ¥7.89 versus a price of ¥17.57, about −55% upside (overvalued).
What is the fair value of 688426?
Our model-based fair value for Jiangsu Cowin Biotech Co. Ltd. A is ¥7.89 (as of Oct 30, 2026), built from audited fundamentals. The current price: ¥17.57.
What is the quality score of 688426?
Jiangsu Cowin Biotech Co. Ltd. A has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jiangsu Cowin Biotech Co. Ltd. A (688426)?
Our model-based price target is the fair value of ¥7.89 (as of Oct 30, 2026) from 1 valuation models. Cautious scenario ¥5.21, optimistic scenario ¥9.86. It is a calculation from audited fundamentals, not an analyst target.
What is the Jiangsu Cowin Biotech Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥7.89, about −55% upside versus a price of ¥17.57 (overvalued). Cautious scenario ¥5.21, optimistic scenario ¥9.86. The calculation is refreshed regularly with new filings.
What is the revenue of Jiangsu Cowin Biotech Co. Ltd. A (688426)?
Jiangsu Cowin Biotech Co. Ltd. A reported trailing-twelve-month revenue of about 219M CNY (latest available figure, as of Oct 30, 2026).
Does Jiangsu Cowin Biotech Co. Ltd. A pay a dividend?
Jiangsu Cowin Biotech Co. Ltd. A currently shows a dividend yield of 0.01% relative to its recent price (as of Oct 30, 2026).
What is the intrinsic value of Jiangsu Cowin Biotech Co. Ltd. A (688426)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jiangsu Cowin Biotech Co. Ltd. A it is ¥7.89 per share (as of Oct 30, 2026), against a price of ¥17.57. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Jiangsu Cowin Biotech Co. Ltd. A stock overvalued or undervalued in 2026?
As of Oct 30, 2026, 688426 trades above its calculated fair value: price ¥17.57, fair value ¥7.89, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688426?
No. The price is what the market pays today (¥17.57); the fair value is what the company's own numbers justify (¥7.89). For Jiangsu Cowin Biotech Co. Ltd. A the two are ¥9.68 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jiangsu Cowin Biotech Co. Ltd. A worth?
The market values Jiangsu Cowin Biotech Co. Ltd. A at about 2.0B CNY (market capitalisation, as of Oct 30, 2026). Per share that is ¥17.57; our models calculate a fair value of ¥7.89 per share.
What do the bullish and bearish scenarios say about 688426?
Our models span a range for Jiangsu Cowin Biotech Co. Ltd. A: cautious scenario ¥5.21, base ¥7.89, optimistic ¥9.86 per share (as of Oct 30, 2026, price ¥17.57). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Jiangsu Cowin Biotech Co. Ltd. A (688426)?
Balance-sheet figures for Jiangsu Cowin Biotech Co. Ltd. A (as of Oct 30, 2026): return on equity −6.6%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 688426 from its 52-week high?
Jiangsu Cowin Biotech Co. Ltd. A trades at ¥17.57, about 47% below its 52-week high of ¥33.46 and 18% above the low of ¥14.95 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥7.89 is for.
Which stocks are comparable to Jiangsu Cowin Biotech Co. Ltd. A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jiangsu Cowin Biotech Co. Ltd. A stock attractive at the current price?
The data as of Oct 30, 2026: price ¥17.57, calculated fair value ¥7.89 (−55%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688426 calculated?
We run Jiangsu Cowin Biotech Co. Ltd. A through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥7.89, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Jiangsu Cowin Biotech Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jiangsu Cowin Biotech Co. Ltd. A (688426)?
The closing price on Oct 30, 2026 was ¥17.57. Our model-based fair value is ¥7.89, about −55% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jiangsu Cowin Biotech Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥9.86). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥5.21 to ¥9.86) leaves room in how you read the outcome.
Key figures of Jiangsu Cowin Biotech Co. Ltd. A
How large is the market capitalisation of Jiangsu Cowin Biotech Co. Ltd. A (688426)?
The market capitalisation of Jiangsu Cowin Biotech Co. Ltd. A is 2.0B CNY (≈ $297M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jiangsu Cowin Biotech Co. Ltd. A (688426)?
The price-to-sales ratio of Jiangsu Cowin Biotech Co. Ltd. A is 9.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jiangsu Cowin Biotech Co. Ltd. A (688426)?
Earnings per share at Jiangsu Cowin Biotech Co. Ltd. A are ¥−0.7600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jiangsu Cowin Biotech Co. Ltd. A (688426)?
The dividend yield of Jiangsu Cowin Biotech Co. Ltd. A is 0.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jiangsu Cowin Biotech Co. Ltd. A (688426)?
The net margin of Jiangsu Cowin Biotech Co. Ltd. A is −39.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jiangsu Cowin Biotech Co. Ltd. A (688426)?
The return on equity (ROE) of Jiangsu Cowin Biotech Co. Ltd. A is −6.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jiangsu Cowin Biotech Co. Ltd. A (688426)?
On an EBIT basis the return on assets of Jiangsu Cowin Biotech Co. Ltd. A is 1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jiangsu Cowin Biotech Co. Ltd. A (688426)?
The operating margin of Jiangsu Cowin Biotech Co. Ltd. A is −50.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jiangsu Cowin Biotech Co. Ltd. A (688426)?
Revenue at Jiangsu Cowin Biotech Co. Ltd. A is growing +22.5% versus a year earlier (3y avg −28.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jiangsu Cowin Biotech Co. Ltd. A (688426)?
Earnings per share at Jiangsu Cowin Biotech Co. Ltd. A are growing −93.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Jiangsu Cowin Biotech Co. Ltd. A (688426) generate?
The free cash flow of Jiangsu Cowin Biotech Co. Ltd. A is −93.8M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Jiangsu Cowin Biotech Co. Ltd. A in the live analysis
One click puts Jiangsu Cowin Biotech Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 30, 2026